Long-term Outcomes of Primary Percutaneous Coronary Intervention with Second-generation Drug-eluting Stents in ST-elevation Myocardial Infarction Patients Caused by Very Late Stent Thrombosis
- PMID: 28397722
- PMCID: PMC5407039
- DOI: 10.4103/0366-6999.204111
Long-term Outcomes of Primary Percutaneous Coronary Intervention with Second-generation Drug-eluting Stents in ST-elevation Myocardial Infarction Patients Caused by Very Late Stent Thrombosis
Abstract
Background: The ST-segment elevation myocardial infarction (STEMI) patients due to stent thrombosis (ST) remain a therapeutic challenge for a clinician. Till date, very few researches have been conducted regarding the safety and effectiveness of primary percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) for STEMI caused by very late ST (VLST). This retrospective study evaluated the safety, efficacy, and outcomes of primary PCI with second-generation DES for STEMI due to VLST compared with primary PCI for STEMI due to de novo lesion.
Methods: Between January 2007 and December 2013, STEMI patients with primary PCI in Fuwai Hospital had only second-generation DES implanted for de novo lesion (558 patients) and VLST (50 patients) were included in this retrospective study. The primary end points included cardiac death and reinfarction. The secondary end points included cardiac death, reinfarction, and target lesion revascularization. Continuous variables were expressed as mean (standard deviation) or median (interquartile range) and compared by Student's t- test or Mann-Whitney U-test as appropriate. Categorical variables were expressed as counts and percentages, and comparison of these variables was performed with Chi-square or Fisher's exact test. A two-tailed value of P < 0.05 was considered statistically significant for all comparisons. Statistical analyses were performed by SAS software (version 9.4, SAS Institute Inc., Cary, USA) for Windows.
Results: In-hospital primary end point and the secondary end point were no significant differences between two groups (P = 1.000 and P = 1.000, respectively). No significant differences between two groups were observed according to the long-term primary end point and the secondary end point. Kaplan-Meier survival curves showed no significant difference between the two groups in the primary end point and the secondary end point at 2 years (P = 0.340 and P = 0.243, respectively). According to Cox analysis, female, intra-aortic balloon pump support, and postprocedural thrombolysis in myocardial infarction flow 3 were found to be independent predictors for long-term follow-up.
Conclusion: Primary PCI with second-generation DES is a reasonable choice for STEMI patients caused by VLST.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.Circulation. 2009 Sep 15;120(11):964-72. doi: 10.1161/CIRCULATIONAHA.108.830372. Epub 2009 Aug 31. Circulation. 2009. Retraction in: Circulation. 2010 Mar 2;121(8):e228. doi: 10.1161/CIR.0b013e3181d70edb. PMID: 19720939 Retracted. Clinical Trial.
-
Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial.Am Heart J. 2009 Oct;158(4):e43-50. doi: 10.1016/j.ahj.2009.03.016. Am Heart J. 2009. PMID: 19781402 Clinical Trial.
-
5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.JACC Cardiovasc Interv. 2011 Jan;4(1):24-9. doi: 10.1016/j.jcin.2010.11.003. JACC Cardiovasc Interv. 2011. PMID: 21251625 Clinical Trial.
-
Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.Arch Intern Med. 2012 Apr 23;172(8):611-21; discussion 621-2. doi: 10.1001/archinternmed.2012.758. Arch Intern Med. 2012. PMID: 22529227 Review.
-
Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention.Am J Cardiol. 2013 May 1;111(9):1295-304. doi: 10.1016/j.amjcard.2013.01.281. Epub 2013 Mar 12. Am J Cardiol. 2013. PMID: 23490029 Review.
Cited by
-
The outcome of primary percutaneous coronary intervention in patients with stent thrombosis.Indian Heart J. 2022 Nov-Dec;74(6):464-468. doi: 10.1016/j.ihj.2022.11.003. Epub 2022 Nov 8. Indian Heart J. 2022. PMID: 36368606 Free PMC article.
-
Hemodynamic Support Devices for Shock and High-Risk PCI: When and Which One.Curr Cardiol Rep. 2017 Aug 31;19(10):100. doi: 10.1007/s11886-017-0905-3. Curr Cardiol Rep. 2017. PMID: 28856523 Review.
-
Comparison of Efficacy and Safety between First- and Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndrome.Chin Med J (Engl). 2018 Jun 20;131(12):1397-1405. doi: 10.4103/0366-6999.233959. Chin Med J (Engl). 2018. PMID: 29893356 Free PMC article.
References
-
- Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation. 2009;119:1634–42. doi: 10.1161/CIRCULATIONAHA.108.813667. - PubMed
-
- Kristensen SL, Galløe AM, Thuesen L, Kelbæk H, Thayssen P, Havndrup O, et al. Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: A five year follow-up of the SORT OUT II study. PLoS One. 2014;9:e113399. doi: 10.1371/journal.pone.0113399. - PMC - PubMed
-
- Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J. 2014;35:2541–619. doi: 10.1093/ejcts/ezu366. - PubMed
-
- Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents 5-year follow-up of the Endeavor III (A randomized controlled trial of the medtronic endeavor drug [ABT-578] eluting coronary stent system versus the cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions) JACC Cardiovasc Interv. 2011;4:543–50. doi: 10.1016/j.jcin.2010.12.014. - PubMed
-
- Writing Committee Members, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–327. doi: 10.1161/CIR.0b013e31829e8776. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous